| April 12, 2011 | | News | sanofi Completes Genzyme Acquisition
Stephanie Sutton
sanofi-aventis has gained full control over Genzyme, bringing the much talked about acquisition deal between the two companies to a close.
More | Pfizer's Capsugel Fetches $2.375 Billion
Rich Whitworth
After completing a strategic review of options for its Capsugel business, Pfizer announced on Apr. 04, 2011 that Kohlberg Kravis Roberts & Co L.P. agreed to acquire the pharmaceutical and dietary capsule company.
More | Nigeria Looks to Simple Packaging Controls and International Cooperation to Curb Counterfeit Drugs
Amy Ritter
The distribution of counterfeit drugs is a serious problem in Nigeria, as in many developing nations, driven by the desire of an impoverished population for drugs at the lowest possible price.
More | J&J Reorganizes Consumer Group
Erik Greb
On Apr. 4, Johnson & Johnson instituted a new structure for its Consumer Group.
More |
| | Ideal Tubing for Aseptic Welds & Heat Sealing
AdvantaFlex® biopharmaceutical tubing also outlasts similar tubing tested in peristaltic pumps by 6 to 10 times. It's free of silicone oils and animal-derived ingredients and contains fewer extractables than other tubing. AdvantaFlex complies with USP Class VI, ISO, EP, and FDA standards. Made in USA.  http://www.advantapure.com/advantaflex.htm |
| | Discovery Pipeline | A common skin allergy can be treated with nanoparticles
Allergic reactions to nickel are a common occurrence. Nanoparticles suspended in a skin cream effectively sequester nickel, and may provide relief for individuals suffering from this allergy. (Nature Nanotechnology)
More | A promising target for an AIDS vaccine
Investigators have used antibodies against a portion of HIV's protein envelope called the V3 loop to provide protection against a different strain of the virus in Macaque monkeys. Development of a vaccine that targets this portion of the virus might confer immunity against multiple genetic subtypes of HIV-1. (PloS One)
More | An "inactive" group of proteins are active after all
University of Pittsburgh and Stanford researchers have found that pseudokinases—enzymes similar in structure to kinases, but which have lost the ability to transfer phosphate groups, are essential for pathogenicity in Toxoplasma gondii. Researchers had previously assumed that these enzymes were inactive, but this finding reveals that they have an essential function in pathogen-based disease. (Proceedings of the National Academy of Sciences)
More |
| Real-Time Scheduling of Biopharmaceutical Operations
APRIL 14, AT 1-2PM PACIFIC TIME
Biopharmaceutical manufacturing equipment and labor are expensive, finite and often shared across multiple processes. In this webinar we will describe the limitations of the today's mostly simplistic Microsoft Project-like scheduling tools and why these result in sub-optimal plans (along with a continued reliance on Excel). We will provide real-world examples of a way to schedule biomanufacturing plant operations in real time using Bio-G's Simulation platform, which takes account of the complexity of the process, the finite and shared nature of facility resources, plus the need for split-second re-scheduling. Please click below to participate in our complementary webinar at  http://info.bio-g.com/webinar/RTS.html |
| | Company/People Notes | | ATMI, a provider of single-use components, formed a distribution pact with Finesse, a manufacturer of measurement and control systems. The deal gives ATMI the right to sell Finesse T700 control systems with the ATMI single-use Integrity PadReactor system. The combined turnkey system will provide the single-use market with a ready-to-use bioreactor platform. | | The biopharmaeutical company Biota Scientific Management received a $231 million contract from US government to produce laninamivir. The contract is designed to provide US-based manufacturing and clinical data to support a new drug application for laninamivir to the US Food and Drug Administration. | | Daiichi Sankyo began operations of vaccine joint venture, Kitasato Daiichi Sankyo, whose principle business will be manufacturing and marketing biological products for humans and animals and research and development (R&D) of vaccines with Kitasato University, other domestic and overseas universities, and research institutes. | | Dainippon Sumitomo Pharma has formed a drug-development pact with the biopharmaceutical company Intercept Pharmaceutical for the development and commercialization of Intercept’s FXR agonist obeticholic acid (OCA). DSP will advance OCA in Japan and China for the treatment of chronic liver diseases, with an initial focus on primary biliary cirrhosis and nonalcoholic steatohepatitis. | | Fujifilm Diosynth Biotechnologies, the former Merck Biomanufacturing Network, began operations under its new name following the completion of the acquisition of the Merck Biomanufacturing Network by Fujifilm. Fujifilm Diosynth Biotechnologies will provide contract biologics development and manufacturing services. | | The biopharmaceutical company Gilead Sciences and Yale University signed a R&D pact that will initially span four years with an option to renew for up to 10 years. Gilead will provide $40 million in research support and basic science infrastructure development during the initial four-year period and will provide a total of up to $100 million over 10 years should the collaboration be extended through that timeframe. Gilead will have the first option to license Yale inventions that result from the collaboration. | | The contract manufacturing organization (CMO) Lonza will invest £16 million ($23 million) to further develop the flexibility and capability of its Slough, UK, biopharmaceutical manufacturing facility to respond to a broader range of customer projects and strengthen its global network of biologics development and manufacturing. | | Merck KGaA formed a strategic and corporate initiative, Merck Serono Israel Bioincubator Fund, which targets Israeli biotechnology start-ups. The incubator program is designed to accelerate the development of entrepreneurial start-up companies and will offer both seed financing and the opportunity of using a dedicated part of Merck Serono’s Israeli research and development center, Interlab, for their own research. Over a seven-year time span, Merck Serono will invest a total of €10 million (about $14 million). | | The specialty pharmaceutical company Valeant Pharmaceuticals made a $5.7 billion bid for the biopharmaceutical company Cephalon. Valeant plans to propose a slate of directors to replace Cephalon's board with its own nominees. | | The biopharmaceutical company Generex Biotechnology made several management changes and has appointed John Barratt, chairman of the company's board of directors. The company has also named Mark Fletcher as president and CEO. In addition, the board has appointed David Brusegard, PhD, as chief operating officer and current vice-president of finance, Stephen Fellows, as acting chief financial officer of Generex to complete its new management team. Gerald Bernstein, MD, will continue as the company's vice-president for medical affairs. |  | | | | Marketplace | | INTERPHEX Asia is the definite sourcing market in Asia for pharmaceutical and biopharmaceutical manufacturing professionals to source for new suppliers and view the latest cutting edge technology. Mark your calendar to visit INTERPHEX Asia 30 - 31 May 2011 at SUNTEC Singapore.
 More Information |  | EXPERIENCE THE FUTURE OF BIOLOGICS.
PEGS - the essential protein engineering summit May 9-13. 2011 Boston, MA
PEGS 2011 encompasses a broad spectrum of topics that are essential to scientists in the pharmaceutical and biotechnology industry. This year's event consists of 12 conference programs within 4 streams, and is focused on the current trends and science in antibody engineering and development. Discovery, Expression, Analytical, Antibodies
The conferences include presentations, interactive panels, technology talks, and numerous networking opportunities. Join over 1200 of your colleagues at this must attend event.  PEGSummit.com. | | 
©2009, Advanstar Communications, Inc.
224 Phillip Morris Drive, Suite 402
Salisbury, MD 21804
| | |  Biopharm International
The Magazine | | Accelerating Bioprocess Optimization
Read More | | Events | Apr. 18-20, 2011: CPhI Japan
Tokyo, Japan
Registration details | Apr. 26-28, 2011: IVT's 12th Annual Computer and Software Validation
Philadelphia, PA
Registration details | May 2-5, 2011: Pharmaceutical Compliance Forum 5th Intl Pharmaceutical Compliance Congress
Istanbul, Turkey
Registration details |  |
No comments:
Post a Comment